A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs

Inclusion Criteria: * 18≤aged\<70 * pathologic diagnosis of invasive breast cancer，staging ii to iii，the diameters≥2cm indicated by MRI or axillary lymph node（+） * Immunohistochemical（IHC） positive for 3+ or FISH（+） * clear hormone receptor（HR） status * Eastern cooperative oncology group(ECOG)=0/1 * LVEF≥55% * pathologic grading of Miller and Payne * screening laboratory values with the following parameters：absolute neutrophils acount：≥1500/mm3,total bilirubin:≤2.0×ULM,Aspartate transaminase (AST)/ALT≤2.5×ULM,platelet≥80000/mm3，serum creatinine≤1.5×ULM * no pregnant or nursing * signed Informed consent forms Exclusion Criteria: * prior exposure to any treatments for breast cancer * inflammatory/Bilateral/IV stage breast cancer * poor physical condition * pregnant or nursing * Cardiac risk（Congestive heart failure、arrhythmia、myocardial infarct、Refractory hypertension（systolic pressure\>180mmHg/diastolic pressure\>100mmHg）） * any other cancer within 5 years prior to screening with the exception of cervical carcinoma and non melanoma skin cancer * Allergic to chemotherapy drugs